Correct. And all that ultimately adds up to safety, efficacy, very low production cost and easy administration of vaccine as well. So many advantages.
Meanwhile, with all these advantages and potentially better in-house combos, why are they bothering to trial those PD1vaxx/Tecentriq and Hervaxx/Keytruda combo trials? Maybe to get data to compare to those potential in-house combos to prove the Professor's point? And if proven, then bidding frenzy?
Ann: Science Series CHECKvacc, page-35
-
- There are more pages in this discussion • 120 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
